Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of NXT007 versus emicizumab prophylaxis in hemophilia A
jRCT2051250252Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in hemophilia A comparing NXT007 prophylaxis with Emicizumab prophylaxis (2 arms). Primary endpoint: Annualized number of treated bleeds (ABR). Started Jun 2026; status: recruiting.
02
Drugs
zemocimigemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2051250252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250252.